Eli Lilly and Company
LLYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeEli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. With a market capitalization of $1.14T, it sits in mega-cap territory. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Market Cap
$1.14T
Beta
0.45
P/E (TTM)
42.75
P/E (Fwd)
26.97
EPS (TTM)
$29.79
EPS (Fwd)
$47.22
ROE
102.3%
ROA
20.4%
Cash
$8.95B
Total Debt
$54.91B
Free CF
$11.07B
52W Change
54.1%
Annual Financials
Cash vs Debt
Where LLY stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, LLY finished 8.72% above its 150-day moving average ($1084.67) and 9.79% above its 200-day moving average ($1074.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LLY overbought or oversold?
At the October 12, 2026 close, LLY's RSI(14) was 54.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, LLY has $8.95B in cash with $54.91B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $11.07B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 102.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 20.4% further supports the picture of efficient asset utilization. Revenue has grown from $28.54B (2022) to $65.18B (2025), reflecting a 128% increase over the period.
With a beta below 0.7, Eli Lilly and Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Eli Lilly and Company carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Eli Lilly and Company and its sector.